This pathway is particularly interesting since the expression of CD99 in T cells is sought to detect minimal residual disease in acute lymphoblastic leukemia [80]; and some clinical trials propose CD99 as a therapeutic target in AML [52,100]. Here, CD99 is linked to acute myeloid leukemia.